🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "major milestone" in the effort against superbug strains of the bacteria, according to scientists.

A Global Challenge

Cases of gonorrhoea are increasing around the world, with estimates suggesting more than 82 million new cases annually. Especially elevated rates are reported in Africa and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. In England, cases have reached a historical peak, while infection numbers across Europe in 2023 were three times higher compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely advancement in the context of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options presently on offer.”

Public health authorities are particularly alarmed about the rise in drug-resistant strains. The WHO has classified it as a "priority pathogen". A tracking program showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Therapies Receive Clearance

One new antibiotic, also known as Nuzolvence, was cleared by the American regulatory agency in December for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers anticipate that specific application of this new drug will help slow the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, was also approved in close succession. This medication, which is employed against UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin was the result of a new, not-for-profit approach for medication research. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone marks a huge turning point in the therapy of superbug gonorrhoea, which until now has been evolving faster than medical innovation.”

Research Study Outcomes and Worldwide Availability

According to data published in a major medical journal, the new drug eradicated the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the existing first-line therapy, which uses an injection and a pill. The study included nearly 1,000 volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its development partnership, GARDP has the authority to register and commercialise the drug in many regions with limited resources.

Doctors directly involved have shared optimism. Access to a one-pill regimen such as this is hailed as a "critical tool" for public health efforts. This is deemed vital to reduce the burden of the infection for patients and to prevent the spread of highly drug-resistant gonorrhoea globally.